LAMICTAL 25 mg/1 (Lamotrigine TABLET, FOR SUSPENSION) 25 mg/1

LAMICTAL 25 mg/1 is a medication used to manage certain types of seizures and mood disorders. This oral suspension is formulated for easy administration and is produced by GlaxoSmithKline LLC in the USA.

Strength

25 mg/1

Pack Size

100 TABLET, FOR SUSPENSION in 1 BOTTLE (0173-0527-00)

Manufacturer / TM Owner

GlaxoSmithKline LLC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

LAMICTAL 25 mg/1 is primarily used as an anticonvulsant to control seizures in conditions like epilepsy. It may also be prescribed for bipolar disorder to stabilize mood. The medication works by affecting the activity of certain chemicals in the brain. Always consult a healthcare provider to determine if this medication is suitable for your condition.

Side Effects

Common effects of LAMICTAL 25 mg/1 may include dizziness, headache, and nausea. Some users might experience blurred vision or coordination issues. These effects vary among individuals and typically subside as the body adjusts to the medication.

Precautions & Warnings

Handle LAMICTAL 25 mg/1 with care, especially if you have a history of allergic reactions to similar medications. It is important to follow the prescribed dosage and administration instructions. Store the medication in a cool, dry place away from direct sunlight.

Avoid Interactions

LAMICTAL 25 mg/1 may interact with other medications, including certain anticonvulsants and hormonal birth control. Alcohol consumption should be avoided as it can enhance the sedative effects. Always inform your healthcare provider about all medications you are taking to avoid potential interactions.

Frequently Asked Questions

LAMICTAL 25 mg/1 is used to manage seizures in epilepsy and to stabilize mood in bipolar disorder.

LAMICTAL 25 mg/1 is taken orally as a suspension. Follow the instructions provided by your healthcare provider for proper administration.

Common side effects may include dizziness, headache, nausea, blurred vision, and coordination issues.

LAMICTAL 25 mg/1 may interact with other medications, so it is important to consult your healthcare provider before combining it with other treatments.

Store LAMICTAL 25 mg/1 in a cool, dry place away from direct sunlight and out of reach of children.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.